Skip To Main Content

Inspiration and Innovation

Get inspired and stay on the cutting edge of innovation with these resources.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
Hear from an expert on what are the main challenges in treating Patients with CRS with Nasal Polyps?

Hear from an expert on what are the main challenges in treating Patients with CRS with Nasal Polyps?

Do historical HbA1c values explain glycemic legacy effect in type 2 diabetes?

Do historical HbA1c values explain glycemic legacy effect in type 2 diabetes?

ATTD 2021: Technology Supporting Initiation, Titration, and Intensification

ATTD 2021: Technology Supporting Initiation, Titration, and Intensification

Hear from an expert on how can you limit the effects of systemic steroid use for Patients with CRS with Nasal Polyps?

Hear from an expert on how can you limit the effects of systemic steroid use for Patients with CRS with Nasal Polyps?

Rethink your Nasal Polyps. Type 2 Inflammation a Nasal Polyps mystery

Rethink your Nasal Polyps. Type 2 Inflammation a Nasal Polyps mystery

Type 2 Inflammation Is The Underlying Cause Of Crswnp In 80% Of Patients.

Type 2 Inflammation Is The Underlying Cause Of Crswnp In 80% Of Patients.

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia

Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines

Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines

Maternal and Perinatal Outcomes of VTE

Maternal and Perinatal Outcomes of VTE

Atopic Dermatitis story

Atopic Dermatitis story

Use of Lipid-Lowering Therapies Over 2 Years

Use of Lipid-Lowering Therapies Over 2 Years

The European experience: Swedeheart and AIFA registries

The European experience: Swedeheart and AIFA registries